Dermapharm Holding SE (Frankfurt:DMP.F)
| Market Cap | 1.91B+18.6% |
| Revenue (ttm) | 1.18B |
| Net Income | 146.54M |
| EPS | 2.77 |
| Shares Out | 49.54M |
| PE Ratio | 13.95 |
| Forward PE | 13.03 |
| Dividend | €0.88(2.33%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 180 |
| Open | 38.65 |
| Previous Close | 37.75 |
| Day's Range | 38.65 - 38.65 |
| 52-Week Range | 32.30 - 50.70 |
| Beta | 0.87 |
| Analysts | none |
| Price Target | 51.00(+31.95%) |
| Earnings Date | Nov 12, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About DMP.F
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DMP.F stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in DMP.F holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DMP.F's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DMP.F Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DMP.F patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DMP.F from public contracts
Source: USAspending.gov
DMP.F Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DMP.F’s recent data — informational, not investment advice